Cytodyn Inc (CYDY)

[Twister]

Incomplete/omission of material information needs regulatory scrutiny!

Unfortunately, the Board of Directors have failed taking necessary immediate corrective actions, thereby allowing these actions to continue.

This deficient pattern regarding releasing material information must be addressed and corrected, seemingly now by securities regulators.
Given ongoing lapses, perhaps a closer look into other Corporate actions/inactions will also become prudent or even necessary.

As a shareholder, I fear these problems/issues beyond that of any drug acceptance, approval delays or even failures.